SA
SKLTY logo
SEEK Limited(SKLTY)
Closing price · checked 11:11 PM ETAbout this dataData status
$16.78▼-0.89 (-5.04%)
Extended:$17.67+0.89 (+5.30%)· 11:11 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

SEEK Limited (SKLTY)

R&D to Revenue

7.13%

Fiscal year · Period ending:

SKLTY logo

SKLTY R&D to Revenue

Latest reported7.13%
SKLTY FY R&D/Revenue (0.00% → 7.13%)
Powered by
High-resolution chart · PNG

What is r&d to revenue?

R&D spending as percentage of revenue.

SKLTY r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it, in percentage points.

SEEK Limited R&D to Revenue — Annual fiscal periods
Period endingR&D to RevenueChange
7.1328%−0.50 pts
7.6299%−0.19 pts
7.8222%+2.22 pts
5.5986%−0.81 pts
6.4129%−0.82 pts
7.234%+0.15 pts
7.0858%+0.69 pts
6.3957%+0.52 pts
5.871%+0.20 pts
5.6735%+0.93 pts
4.7454%+2.72 pts
2.027%+0.09 pts
1.9347%+0.64 pts
1.2899%−4.43 pts
5.7236%−0.10 pts
5.8192%−1.14 pts
6.9572%−1.27 pts
8.2291%−6.94 pts
15.1667%+15.17 pts
0%0.00 pts
0%0.00 pts
0%—

Frequently asked questions: SKLTY r&d to revenue

What is SEEK Limited (SKLTY)'s current r&d to revenue?

SEEK Limited (SKLTY)'s latest reported r&d to revenue (Fiscal year) is 7.13% as of Jun 30, 2026. R&D spending as percentage of revenue.

How much historical r&d to revenue data is available for SKLTY?

Stock Alarm Pro provides 22 dated annual fiscal periods observations for SEEK Limited (SKLTY)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare SKLTY's r&d to revenue to peers or set an alert?

You can open SKLTY's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on SKLTY delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.